A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors

Trial Profile

A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics
  • Acronyms GRANIX
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 6 Nov 2018 to 11 Apr 2018.
    • 01 Sep 2017 Planned primary completion date changed from 29 Jan 2018 to 11 Apr 2018.
    • 26 Apr 2017 Planned End Date changed from 30 Nov 2018 to 6 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top